AstraZeneca Gains Dual US and European Approvals for Rare Disease and Oncology Treatments
AstraZeneca shares rose 0.73% to $185.78 in premarket trading after securing major regulatory clearances in the US and EU for its rare disease drug Klygefa and an oncology combination regimen.
🏢CompaniesPhoto: Benzinga
Key points
- AstraZeneca shares traded up 0.73% to $185.78 in premarket activity.
- Klygefa received US and EU clearance for generalized myasthenia gravis.
- Imfinzi combination therapy secured FDA approval for muscle-invasive bladder cancer.
Pharmaceutical giant AstraZeneca Plc saw its shares climb 0.73% to $185.78 during premarket trading following a string of regulatory approvals across both the United States and the European Union. The agencies cleared the company's rare neuromuscular disease treatment and an oncology regimen aimed at bladder cancer.
The U.S. Food and Drug Administration and European authorities greenlit Klygefa, developed by Alexion, AstraZeneca Rare Disease, for adults suffering from anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In the EU, the therapy was authorized as an add-on to standard care. Klygefa functions as a dual-binding nanobody C5 inhibitor, enabling patients to administer the medication themselves via a once-weekly subcutaneous autoinjector. Approval was supported by data from the pivotal PREVAIL Phase 3 trial.
Separately, the FDA cleared an Imfinzi combination regimen for patients with muscle-invasive bladder cancer who are unable or unwilling to take cisplatin-based chemotherapy. Approximately 16,000 U.S. patients are projected to undergo treatment for this condition in 2026, with up to half unable to tolerate standard cisplatin due to existing health issues or kidney impairment. Data from the VOLGA Phase 3 trial demonstrated that the perioperative regimen reduced the risk of disease progression, recurrence, missed surgery, or death by 49% compared to standard surgery approaches.
What to watch next: Monitor upcoming decisions from regulators in China and other international markets where submissions for Klygefa remain under review.
Source Benzinga — benzinga.com/news/fda/26/11/63285561/astrazeneca-secures-dual-rare-… ↗
Read next
🧠AI AnalysisWalmart Shares Waver Despite Topping Estimates as Growth Momentum Cools
Walmart posted third-quarter results that surpassed analyst expectations, though slower growth rates across key segments prompted market hesitation before the stock recov…
🧠AI AnalysisBitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold
Bitcoin recently traded around $59,090 following a decisive breakdown below the crucial $62,000–$64,000 support zone, shifting short-term market momentum toward sellers.
🧠AI AnalysisBitcoin Tests Support Following Drop Below $60,000 Milestone
Bitcoin recently swept the $55,000 mark before rebounding toward the $59,100 region following a sharp decline that broke previous support levels on November 20.
🧠AI AnalysisEvaluating HF Sinclair and the Turning Oil Refining Cycle
HF Sinclair has experienced impressive expansion driven largely by its refining sector, but market observers suggest the cyclical peak may be near.
🧠AI AnalysisBitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce
Bitcoin remains constrained by a broader bearish pattern on short-term charts as dynamic trendline resistance caps recovery attempts. Although price recently rebounded fr…
🧠AI AnalysisMapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises
A breakdown of a $500 allocation into Infleqtion and Xanadu reveals the high-risk, high-reward nature of early-stage quantum computing investments.